1 rated that in analogy to cyclic urea, cyclic cyanoguanidines also displace the unique structural wate

2 re studies of the HIV PR complex with cyclic cyanoguanidine demonstrated that in analogy to cyclic ur

3 d thio-containing ring systems 3-7 and the N-cyanoguanidine derivative 8.

4                            A series of novel cyanoguanidine derivatives was designed and synthesized.

5 zamides with N-(substituted-pyridin-3-yl)-N'-cyanoguanidines furnished N-{2,2-dichloro-1-[N'-(substit

6     On the basis of this observation, cyclic cyanoguanidines have been designed, synthesized, and eva

7 d inspired by the NAMPT inhibitor APO866 and cyanoguanidine inhibitor scaffolds.

8 tructure-activity relationship of the cyclic cyanoguanidines is compared with that of the correspondi

9         In both groups of rats, pinacidil (a cyanoguanidine K(ATP) agonist; 0.3 to 300 microM) evoked

10 found that bioisosteric replacement of the N-cyanoguanidine moiety of pinacidil (1, Figure 1) with a

11 lockers, the sulfonylurea glyburide, and the cyanoguanidine N-[1-(3-chlorophenyl)cyclobutyl]-N'-cyano

12                         The choice of cyclic cyanoguanidines over cyclic guanidines was based on the

13 s, notably ureas, thioureas, guanidines, and cyanoguanidines, owing in part to their similar capacity

14 as strongly influencing inhibition, with the cyanoguanidine side chain of cimetidine and tiotidine ha

15  We disclose the design of a novel series of cyanoguanidines that are potent (IC(50) approximately 10

16 clohexanones, which were then condensed with cyanoguanidine to form the tetrahydroquinazolines.

17                                       Cyclic cyanoguanidines were found to be very potent inhibitors